Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3867070 · 1 trial · 1 indication
A summary of TEAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
A summary of AEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3867070 (Part A) | EXPERIMENTAL | Single-Ascending Dose of LY3867070 administered orally |
| LY3867070 (Part B) | EXPERIMENTAL | Multiple-Ascending Doses of LY3867070 administered orally |
| LY3867070 (Part C) | EXPERIMENTAL | Multiple Doses of LY3867070 administered orally |
| Placebo (Parts A-C) | PLACEBO_COMPARATOR | Placebo administered orally |
| LY3867070 (Part D) | EXPERIMENTAL | Drug-Drug Interaction (DDI) administered orally |
| Name | Type | Description |
|---|---|---|
| LY3867070 | DRUG | Administered orally |
| Placebo | DRUG | Administered orally |
Inclusion Criteria: * Are overtly healthy as determined by medical evaluation * Part C of the study includes only Japanese and Chinese participants * Have a body weight greater than or equal to 45 kilogram (kg) and also body mass index 18 to 32 kilogram per square meter (kg/m²) inclusive Exclusion...
LY3867070 is an investigational small molecule being studied in healthy participants. It is currently in Phase 1 clinical development, and the ongoing trial is evaluating its safety and tolerability in healthy volunteers. It is not approved for any medical condition.
LY3867070 is being developed by Eli Lilly and Company, a biopharmaceutical company traded on the NYSE under the ticker symbol LLY. The company is conducting a Phase 1 clinical trial of LY3867070 in healthy participants in the United States.
LY3867070 is in Phase 1 clinical development. The drug is investigational and has not been approved by regulatory authorities. It is currently being studied in a single Phase 1 trial that is recruiting healthy participants.
LY3867070 is being evaluated in one Phase 1 clinical trial, identified as NCT07021547, titled "A Study of LY3867070 in Healthy Participants." The trial is recruiting 196 healthy participants in the United States and is a randomized, double-blind, placebo-controlled study.
LY3867070 is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. The ongoing study is designed to assess the safety and tolerability of LY3867070 in healthy participants, and it has not yet been evaluated for efficacy in any patient population.